DocDollars

Argenx Us, Inc.

MA · United States · Reporting entity ID 100001156891

Total reported 2019–2025
$51.7M
#171 of 2,960 reporting companies — 0.1% of all reported industry payments
$14.2M in general payments across 66,389 records, plus $37.5M in research funding across 12,431 records.

How it breaks down

General payments $14,246,229
Research funding $37,456,224

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Argenx Us, Inc. reported $51.7M to US doctors and teaching hospitals from 2019 to 2025, ranking #171 of 2,960 reporting companies. 72% of that was research funding and 28% general payments such as consulting, speaking, food and travel. 66,389 general payment records and 12,431 research records were filed.

Common questions about Argenx Us, Inc.

How much has Argenx Us, Inc. paid US doctors?

Argenx Us, Inc. reported $51,702,453 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $14,246,229 in general payments, $37,456,224 in research funding.

How does Argenx Us, Inc. rank among drug and device companies?

It ranks #171 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Argenx Us, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.